Yearly Budgetary Impact (Model Estimated Outputs).

<p>Yearly Budgetary Impact (Model Estimated Outputs).</p

Model calculated survival curves overlaid with observed clinical trial data [19].

<p>The survival curves derived from the estimated model were similar to those found in previous reported clinical trial data [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0134587#pone.0134587.ref019" target="_blank">19</a>]</p

Clinical Transition Probabilities.

<p>Clinical Transition Probabilities.</p

Markov model of first-line chemotherapy with three disease states.

<p>Markov model of first-line chemotherapy with three disease states.</p

One-way sensitivity analyses based on the third-year budgetary impact.

<p>The estimated model was most sensitive to changes in the cost of ATO in the consolidation phase, in parameters determining the number of patients with APL, and in the cost of in-patient treatment and monitoring of AIDA patients during consolidation.</p

Cumulative Patient Counts by Health State at Year End (Model Estimated Outputs).

<p>^†The total number of patients may not add up to 82 per year due to rounding.</p><p>Cumulative Patient Counts by Health State at Year End (Model Estimated Outputs).</p